Search
Octocrylene
go.drugbank.com/drugs/DB09535ApprovedOctocrylene is a compound often used as an additive in sun screen, and is thought to have skin moisturizing effects because of its emollient properties. … Because of its effectiveness, the chemical has been approved across the globe for use in cosmetics and skin care products, but the concentrations of this ingredient are usually limited to no more than
Mixtures: The Ordinary Invisible Uv Filters SPF 35, The Ordinary Suncare Invisible UV Filters with Antioxidants SPF35Midostaurin
go.drugbank.com/drugs/DB06595ApprovedInvestigationalIt was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. … It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors [A19108].
Synonyms: 4'-N-benzoylstaurosporineCilastatin
go.drugbank.com/drugs/DB01597ApprovedInvestigationalSince the antibiotic, [imipenem], is one such antibiotic that is hydrolyzed by dehydropeptidase, cilastatin is used in combination with imipenem to prevent its metabolism. … [L7628] A newer triple-drug product was approved in July 2019 under the trade name Recarbrio which also contains [relebactam].[L4894]
Mixtures: Primaxin Im, Primaxin IVSerplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalIt was first approved in China - where it is indicated for a number of different cancers[L52963] - and has since been approved in several southeast Asian countries. … Most recently, it was approved in the EU in February 2025 for the treatment of extensive-stage small cell lung cancer.[L52968,L52953]
Ciclopirox
go.drugbank.com/drugs/DB01188ApprovedInvestigationalIn particular, the agent is especially effective in treating Tinea versicolor. … Ciclopirox olamine (used in preparations called Batrafen, Loprox, Mycoster, Penlac and Stieprox) is a synthetic antifungal agent for topical dermatologic treatment of superficial mycoses.
Lumacaftor
go.drugbank.com/drugs/DB09280ApprovedInvestigational, and improvements in CF symptoms. … results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes.
Penpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigational[A273843,A273848] Penpulimab-kcqx was approved by the US FDA in April 2025 for the treatment of nasopharyngeal carcinoma in select patients.[L52993,L52998] … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.
Vepdegestrant
go.drugbank.com/drugs/DB19006ApprovedInvestigational[A275508] Specifically, vepdegestrant is being developed as a first-line or subsequent treatment option for patients whose tumors grow in response to estrogen and have progressed after standard therapies … [A275507, A275509] In a global, randomized Phase III clinical trial (VERITAC-2), vepdegestrant was clinically evaluated and compared against the injectable selective estrogen receptor degrader (SERD) [
Gedatolisib
go.drugbank.com/drugs/DB11896ApprovedInvestigationalbreast cancer without a PIK3CA mutation detected, following progression on or after at least one line of endocrine therapy in the metastatic setting. … [L63796,L63927] The PI3K/AKT/mTOR pathway is a long-standing target in the breast cancer setting, with previously approved agents acting on a single node of it (i.e. PI3Kα, AKT, or mTORC1).
Categories: Class I Phosphatidylinositol 3-Kinases, antagonists & inhibitorsFacial Skin Wrinkles
go.drugbank.com/conditions/DBCOND0057699Drugs: Botulinum toxin type ASynonyms: Lined face